Thunen Shelley B — SEC Form 4 filings
SEC reporting owner CIK 1297491. 19 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2024-01-29 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 21 legs across 7 filings — 130,174 shares, $6,574,496 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 35.
- Largest priced transaction: sale of 31,772 shares @ $47.11 ($1,496,706) in RxSight, Inc., filed 2024-01-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| RxSight, Inc. (RXST) | See remarks | 12 | — | 21 legs · 130,174 sh · $6,574,496 | 27 |
| AEON Biopharma, Inc. (AEON) | Director | 4 | — | — | 5 |
| LENZ Therapeutics, Inc. (LENZ) | Director | 3 | — | — | 3 |
Form 4 filings — Thunen Shelley B
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | AEON Biopharma, Inc. (AEON) | Grant/award (A): 222,684 @ $0 | EDGAR |
| 2026-06-15 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | AEON Biopharma, Inc. (AEON) | Grant/award (A): 308,641 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | RxSight, Inc. (RXST) | Option exercise (M): 7,792 @ $4.34 · Option exercise (M): 6,405 (derivative) @ $0 · Option exercise (M): 1,387 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | RxSight, Inc. (RXST) | Option exercise (M): 15,000 @ $16 · Sale (S): 5,201 @ $47.96 · Sale (S): 9,521 @ $48.69 · Sale (S): 278 @ $49.45 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | AEON Biopharma, Inc. (AEON) | Grant/award (A): 36,021 @ $0 · Grant/award (A): 96,210 (derivative) @ $0 | EDGAR |
| 2024-08-08 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | RxSight, Inc. (RXST) | Option exercise (M): 16,505 @ $4.34 · Option exercise (M): 11,235 (derivative) @ $0 · Option exercise (M): 5,270 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | RxSight, Inc. (RXST) | Option exercise (M): 10,000 @ $15.60 · Sale (S): 8,146 @ $58.41 · Sale (S): 1,854 @ $59.48 · Sale (S): 6,599 @ $58.55 · Sale (S): 1,803 @ $59.56 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-02 | 4 | RxSight, Inc. (RXST) | Option exercise (M): 10,247 @ $15.60 · Sale (S): 9,620 @ $52.68 · Sale (S): 380 @ $53.04 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | RxSight, Inc. (RXST) | Sale (S): 8,857 @ $49.81 · Sale (S): 800 @ $50.27 · Sale (S): 8,938 @ $49.81 · Sale (S): 662 @ $50.24 · Sale (S): 200 @ $50.37 · Sale (S): 543 @ $51.50 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | AEON Biopharma, Inc. (AEON) | Grant/award (A): 16,260 (derivative) @ $0 | EDGAR |
| 2024-03-06 | 4 | RxSight, Inc. (RXST) | Grant/award (A): 92,200 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | RxSight, Inc. (RXST) | Option exercise (M): 10,000 @ $15.60 · Sale (S): 1,166 @ $54.95 · Sale (S): 6,361 @ $56.38 · Sale (S): 2,473 @ $57.03 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-02-07 | 4 | RxSight, Inc. (RXST) | Option exercise (M): 6,900 @ $4.34 · Option exercise (M): 9,125 @ $14.95 · Sale (S): 9,125 @ $47.02 · Option exercise (M): 15,875 @ $14.95 · Sale (S): 15,875 @ $47.47 · Option exercise (M): 6,900 (derivative) @ $0 · +2 more | EDGAR |
| 2024-01-29 | 4 | RxSight, Inc. (RXST) | Option exercise (M): 4,500 @ $4.34 · Option exercise (M): 31,772 @ $15.08 · Sale (S): 31,772 @ $47.11 · Option exercise (M): 4,500 (derivative) @ $0 · Option exercise (M): 31,772 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1297491 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →